Embecta Corp.'s stock plunged 5.99% on Thursday's trading session, following the release of its fiscal Q1 2025 earnings report.
The medical device company reported adjusted earnings of $0.65 per share for the quarter ended December 31, exceeding analysts' expectations of $0.44. However, Embecta lowered its full-year 2025 revenue guidance to $1.08 billion to $1.09 billion, down from the previous range of $1.09 billion to $1.11 billion. This reduced outlook weighed on investor sentiment, leading to the stock's decline.
Despite the revenue guidance cut, Embecta maintained its adjusted earnings per share forecast for fiscal 2025 at $2.70 to $2.90, in line with analysts' estimates of $2.80. The company also reported a dividend of $0.15 for the quarter.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。